Jiangsu Hansoh registers Phase 3 trial of HS-10382 in newly diagnosed Ph+ CML-CP
The study, led by Jiangsu Hansoh Pharmaceutical Co., Ltd., plans to enroll 408 participants and has a planned start date of December 2026. It evaluates the efficacy of oral HS-10382 versus investigator-selected TKIs-imatinib, nilotinib, dasatinib, and flumatinib-in adult patients with newly diagnosed Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia.
Primary source
ClinicalTrials.gov registry record, October 21, 2026
A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Read the source: A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation